| Drug Name: | Mifepristone (84371-65-3) |
|---|---|
| PubChem ID: | 55245 |
| SMILES: | CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O |
| InchiKey: | VKHAHZOOUSRJNA-GCNJZUOMSA-N |
| Therapeutic Category: | Abortifacient Agents, Contraceptive Agents, Contraceptives, Hormone Antagonists, Hormones, Luteolytic Agents, Menstruation-Inducing Agents, Reproductive Control Agents |
| Molecular Weight (dalton) | : | 429.604 |
| LogP | : | 5.4065 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 3 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 40.54 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Hyperphagia | Neuropeptide Y (P01303) | ENHANCED expression of preproNPY mRNA in the arcuate nucleus in obese Zucker rats during repeated administration of mifepristone suggesting an involvement of NPY in the pathophysiology of the hyperphagic syndrome [ ADR Type 2 ] | Effects of repeated administration of mifepristone and 8-OH-DPAT on expression of preproneuropeptide Y mRNA in the arcuate nucleus of obese Zucker rats |
| Obesity | Neuropeptide Y (P01303) | ENHANCED expression of preproNPY mRNA in the arcuate nucleus in obese Zucker rats during repeated administration of mifepristone suggesting genetically determined obesity in Zucker rats [ ADR Type 2 ] | Effects of repeated administration of mifepristone and 8-OH-DPAT on expression of preproneuropeptide Y mRNA in the arcuate nucleus of obese Zucker rats |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category